Clinical Trials
204 trialsReduced-intensity, Related-donor Bone Marrow Transplantation Followed by High-dose Cyclophosphamide for Hematologic Cancers
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
Masonic Cancer Center, University of Minnesota
Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation
Fred Hutchinson Cancer Center
A Phase II Study of the Combination of Ponatinib With Mini-hyper CVD Chemotherapy and Venetoclax in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation
M.D. Anderson Cancer Center
Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia
St. Jude Children's Research Hospital
GastrExtub
Hospices Civils de Lyon
CAR-20/19-T
Medical College of Wisconsin
Phase II Study to Evaluate Safety and Efficacy of CB-103 With Venetoclax in Adolescent and Young Adult Patients With Relapsed/Refractory T-ALL or T-LBL
M.D. Anderson Cancer Center
UPCC 25406
Abramson Cancer Center at Penn Medicine
Levocarnitine and Vitamin B Complex in Treating PEG-Asparaginase or Inotuzumab Ozogamicin-Induced Hyperbilirubinemia in Patients With Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
M.D. Anderson Cancer Center
Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer
Roswell Park Cancer Institute
Phase l/II Study of Ruxolitinib for Acute Leukemia
M.D. Anderson Cancer Center
A Triple-targeted Cell Preparation Targeting CD19/CD20/CD22 in Patients With Relapsed/Refractory B-cell Acute Lymphocytic Leukemia
Institute of Hematology & Blood Diseases Hospital, China
DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With Pembrolizumab
University of Michigan Rogel Cancer Center
Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia
M.D. Anderson Cancer Center
A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives
Thomas Jefferson University
Flumatinib Versus Imatinib Combined With Chemotherapy for de Novo Ph+ ALL
Institute of Hematology & Blood Diseases Hospital, China
Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors
Memorial Sloan Kettering Cancer Center
Phase I Study of GNKG168 in Acute Lymphoblastic Leukemia and Acute Myelogenous Leukemia
Therapeutic Advances in Childhood Leukemia Consortium
Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers
Fred Hutchinson Cancer Center
Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia
M.D. Anderson Cancer Center
T-cell Receptor α/β Depleted Donor Lymphocyte Infusion
Baptist Health South Florida
Study of Sequential CAR-T Cell Treating Leukemia Children
Beijing Boren Hospital
Donor-Derived CD5 CAR T Cells in Subjects with Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia
Beijing Boren Hospital
Pona-CELL
Institute of Hematology and Blood Transfusion, Czech Republic
Haploidentical Stem Cell Transplantation Using Post-Transplant Cyclophosphamide
Loyola University
Family-Based Behavioral Treatment for Childhood Survivors of Acute Lymphoblastic Leukemia
Washington University School of Medicine
huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia
Fred Hutchinson Cancer Center
Oral Health Condition and Quality of Life in Children With Leukemia
University of Sao Paulo
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL)
Therapeutic Advances in Childhood Leukemia Consortium
Ipilimumab and Local Radiation for Selected Solid Tumors
Stanford University
ALL SCTped 2012 FORUM Add-on Study Blina Post HSCT
St. Anna Kinderkrebsforschung
Acute Lymphoblastic Leukemia Therapies Informed by Genomic Analyses
New Mexico Cancer Research Alliance
Window Trial to Evaluate Molecular Response to PI3K Inhibition With Copanlisib in r/r Adult B-cell ALL
Duke University
Study of Moxetumomab Pasudotox in Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL)
M.D. Anderson Cancer Center
Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer
University of Nebraska
Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies
Rutgers, The State University of New Jersey
CART19 in Adult Patients With Minimal Residual Disease During Upfront Treatment for ALL
University of Pennsylvania
SeluDex
University of Birmingham
N-Acetylcysteine vs Placebo as Adjunctive Treatment in Pediatric Leukemia
Dr Cipto Mangunkusumo General Hospital
Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies
Fred Hutchinson Cancer Center
CD3/CD19 Haplo
University Hospital Tuebingen
Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma
University of California, San Diego
T-cell Depleted Alternative Donor Transplantation
Wake Forest University Health Sciences
ALL2518
Gruppo Italiano Malattie EMatologiche dell'Adulto
IMRT-TMI With Fludarabine as Myeloablative Conditioning for Allogeneic HSCT
Indiana University